228 related articles for article (PubMed ID: 38340237)
61. Basic Therapeutic Approach for Patients with Plaque Psoriasis: Korean Expert Consensus Using the Modified Delphi Method.
Jo SJ; Baek YS; Kim TG; Jeong KH; Kim JE; Choi YS; Kim B; Lee ES; Choe YB;
Ann Dermatol; 2023 Jun; 35(3):173-182. PubMed ID: 37290951
[TBL] [Abstract][Full Text] [Related]
62. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
63. Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis.
Guenther L; Turchin I; Vender R; Albrecht LE; Maari C; Yanofsky H; Prajapati VH
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38916719
[TBL] [Abstract][Full Text] [Related]
64. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT; Gooderham M; Papp K
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
[TBL] [Abstract][Full Text] [Related]
65. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
66. Expert recommendations on treating psoriasis in special circumstances.
Carrascosa JM; Belinchón I; de-la-Cueva P; Izu R; Luelmo J; Ruiz-Villaverde R
Actas Dermosifiliogr; 2015 May; 106(4):292-309. PubMed ID: 25595327
[TBL] [Abstract][Full Text] [Related]
67. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis.
Zozaya N; Abdalla F; Alfonso Zamora S; Balea Filgueiras J; Carrascosa Carrillo JM; Delgado Sánchez O; Dolz Sinisterra F; García-Ruiz A; Herranz Pinto P; Manfredi A; Martínez Olmos J; Morales de Los Ríos Luna P; Puig L; Ros S; HIdalgo-Vega Á
Expert Rev Pharmacoecon Outcomes Res; 2022 Sep; 22(6):941-953. PubMed ID: 35404728
[TBL] [Abstract][Full Text] [Related]
68. Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.
Simopoulou T; Tsiogkas SG; Zafiriou E; Bogdanos DP
Drugs Today (Barc); 2023 Mar; 59(3):135-167. PubMed ID: 36847624
[TBL] [Abstract][Full Text] [Related]
69. Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies.
Sánchez-Rodríguez G; Puig L
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373452
[TBL] [Abstract][Full Text] [Related]
70. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
Armstrong AW; Read C
JAMA; 2020 May; 323(19):1945-1960. PubMed ID: 32427307
[TBL] [Abstract][Full Text] [Related]
71. Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement.
Fargnoli MC; Bardazzi F; Bianchi L; Dapavo P; Fabbrocini G; Gisondi P; Micali G; Offidani AM; Pellacani G; Skroza N; Angileri RG; Burlando M; Campanati A; Carrera CG; Chiricozzi A; Conti A; Simone C; Di Lernia V; Errichetti E; Galluzzo M; Guarneri C; Lasagni C; Lembo S; Loconsole F; Megna M; Musumeci ML; Prignano F; Richetta AG; Trovato E; Venturini M; Peris K; Pinton PC
J Clin Med; 2023 May; 12(10):. PubMed ID: 37240650
[TBL] [Abstract][Full Text] [Related]
72. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Sano S; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 Feb; 50(2):e41-e68. PubMed ID: 36582113
[TBL] [Abstract][Full Text] [Related]
73. Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara Pinton P; Chimenti S; Martini P; Peserico A; Puglisi Guerra A; Vena GA;
J Dermatolog Treat; 2015 Apr; 26(2):128-33. PubMed ID: 24708158
[TBL] [Abstract][Full Text] [Related]
74. Update on the Management of Pediatric Psoriasis: An Italian Consensus.
Peris K; Fortina AB; Bianchi L; Fabbrocini G; Gisondi P; Balato A; Bardazzi F; Bernardini N; Bonamonte D; Bongiorno MR; Buligan C; Cusano F; Del Giudice MBF; El Hachem M; Fargnoli MC; Gualdi G; Guarneri C; Hansel K; Malara G; Mazzatenta C; Micali G; Narcisi A; Neri I; Oranges T; Panzone M; Parodi A; Restano L; Simonetti O; Venturini M; Di Lernia V
Dermatol Ther (Heidelb); 2022 Aug; 12(8):1753-1775. PubMed ID: 35776408
[TBL] [Abstract][Full Text] [Related]
75. Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials.
Qiu Y; Zhu Y; Liu Y; Liu Q
J Dermatolog Treat; 2023 Dec; 34(1):2199106. PubMed ID: 37010492
[TBL] [Abstract][Full Text] [Related]
76. Secukinumab for treating plaque psoriasis.
Rothstein B; Gottlieb A
Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
[TBL] [Abstract][Full Text] [Related]
77. Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study.
Asahina A; Okubo Y; Morita A; Tada Y; Igarashi A; Langley RG; Deherder D; Matano M; Vanvoorden V; Wang M; Ohtsuki M; Nakagawa H
Dermatol Ther (Heidelb); 2023 Mar; 13(3):751-768. PubMed ID: 36648594
[TBL] [Abstract][Full Text] [Related]
78. Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis.
Bagel J; Tatla D; Hellot S; Knapp B; Murphy C; Peterson L; Sebastian M
J Drugs Dermatol; 2022 Feb; 21(2):162-171. PubMed ID: 35133113
[TBL] [Abstract][Full Text] [Related]
79. Management of pediatric plaque psoriasis using biologics.
Lansang P; Bergman JN; Fiorillo L; Joseph M; Lara-Corrales I; Marcoux D; McCuaig C; Pope E; Prajapati VH; Li SZJ; Landells I
J Am Acad Dermatol; 2020 Jan; 82(1):213-221. PubMed ID: 31150699
[TBL] [Abstract][Full Text] [Related]
80. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium.
Carmona-Rocha E; Puig L
Immunotherapy; 2023 Oct; 15(15):1209-1225. PubMed ID: 37609785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
